DrugDashboards

Betamethasone Sodium Phosphate and Betamethasone Acetate

Betamethasone Sodium Phosphate and Betamethasone Acetate · BETAMETHASONE ACETATE 3 mg/mL; BETAMETHASONE SODIUM PHOSPHATE 3 mg/mL · Injection, Suspension · Intra-Articular; Intralesional; Intramuscular · Asclemed USA, Inc.

NDC 76420-0007-05 · 5 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for betamethasone sodium phosphate and betamethasone acetate (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA090747
TE code
AB
Approval date
Jul 31, 2009
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Betamethasone Sodium Phosphate and Betamethasone Acetate (Injection, Suspension)

LabelerStrengthFirst seenLast seen
American Regent, Inc.BETAMETHASONE ACETATE 3 mg/mL; BETAMETHASONE SODIUM PHOSPHATE 3 mg/mLJul 15, 2026Sep 3, 2026
Advanced Rx Pharmacy of Tennessee, LLCBETAMETHASONE SODIUM PHOSPHATE 3 mg/mL; BETAMETHASONE ACETATE 3 mg/mLJul 22, 2026Sep 2, 2026
Asclemed USA, Inc.BETAMETHASONE SODIUM PHOSPHATE 3 mg/mL; BETAMETHASONE ACETATE 3 mg/mLJul 22, 2026Sep 2, 2026
Asclemed USA, Inc.BETAMETHASONE ACETATE 3 mg/mL; BETAMETHASONE SODIUM PHOSPHATE 3 mg/mLJul 15, 2026Aug 30, 2026
Advanced Rx Pharmacy of Tennessee, LLCBETAMETHASONE ACETATE 3 mg/mL; BETAMETHASONE SODIUM PHOSPHATE 3 mg/mLJul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Betamethasone Sodium Phosphate and Betamethasone Acetate — NDC 76420-0007-05," retrieved September 3, 2026, https://drugdashboards.com/drug/76420000705.

Free to cite with attribution — see how the data is put together.